DFP-14927 for Cancer

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen ByJaffer Ajani, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Delta-Fly Pharma, Inc.

Must not be taking: Anticoagulants, Antiseizure

Disqualifiers: HIV, HBV, HCV, CNS metastases, others

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot have had chemotherapy, immunotherapy, radiotherapy, or other investigational therapies within 4 weeks before starting the study.

Eligibility Criteria

This trial is for adults over 18 with advanced solid tumors that haven't responded to standard treatments or lack effective treatment options. Specifically, it includes those with certain types of gastroesophageal, pancreatic, or cholangiocarcinoma cancers. Participants must be relatively healthy overall (ECOG status 0-1) and have adequate organ function.

Inclusion Criteria

My kidney function, measured by creatinine levels or clearance, is within the normal range.

My cancer is confirmed and has not responded to standard treatments.

I am fully active or can carry out light work.

I am 18 years old or older.

Participant Groups

The study tests DFP-14927, a new drug given through an IV. It's in Phase I where researchers are trying different doses to see what's safe for people whose solid tumors have stopped responding to regular cancer therapies.

1Treatment groups

Experimental Treatment

Group I: DFP-14927Experimental Treatment1 Intervention

DFP-14927: weekly IV infusion, 28 day treatment cycle